Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Randomized phase II selection study of ramucirumab and paclitaxel versus FOLFIRI in refractory small bowel adenocarcinoma: SWOG S1922.
Authors
Michael J. Overman
University of Texas MD Anderson Cancer Center, Houston, TX
Michael J. Overman , Katherine A Guthrie , Mohamed E. Salem , Katrina Sophia Pedersen , Aparna Kalyan , Shay Bellasea , Philip Agop Philip
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04205968
DOI
10.1200/JCO.2022.40.4_suppl.TPS643
Abstract #
TPS643
Poster Bd #
R5
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Phase II study of FOLFIRI + ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin / fluoropyrimidine (RAINCLOUD).
First Author: Naotoshi Sugimoto
Poster
2015 Gastrointestinal Cancers Symposium
PEPCOL: A randomized noncomparative phase II study of PEP02 (MM-398) or irinotecan in combination with leucovorin and 5-fluorouracil as second-line therapy in patients with unresectable metastatic colorectal cancer—A GERCOR Study.
First Author: Benoist Chibaudel
Poster
2024 ASCO Gastrointestinal Cancers Symposium
HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer (mCRC) refractory to anti-EGFR antibodies.
First Author: Atsushi Ishiguro
Poster
2022 ASCO Gastrointestinal Cancers Symposium
NeoOPTIMIZE: An open-label, phase II trial and biomarker discovery platform to assess the efficacy of adaptive switching of modified FOLFIRINOX (mFFX) or gemcitabine/nab-paclitaxel (GA) as a neoadjuvant strategy for patients with resectable/borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).
First Author: Charles D. Lopez